Inspire Medical Systems, Inc. (NYSE:INSP) shareholders would be excited to see that the share price has had a great month, posting a 42% gain and recovering from prior weakness. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 20% over that time.
Following the firm bounce in price, Inspire Medical Systems' price-to-sales (or "P/S") ratio of 10.5x might make it look like a strong sell right now compared to other companies in the Medical Equipment industry in the United States, where around half of the companies have P/S ratios below 3.4x and even P/S below 1.3x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.
See our latest analysis for Inspire Medical Systems
How Has Inspire Medical Systems Performed Recently?
With revenue growth that's superior to most other companies of late, Inspire Medical Systems has been doing relatively well. The P/S is probably high because investors think this strong revenue performance will continue. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
Want the full picture on analyst estimates for the company? Then our free report on Inspire Medical Systems will help you uncover what's on the horizon.
How Is Inspire Medical Systems' Revenue Growth Trending?
The only time you'd be truly comfortable seeing a P/S as steep as Inspire Medical Systems' is when the company's growth is on track to outshine the industry decidedly.
Retrospectively, the last year delivered an exceptional 64% gain to the company's top line. Spectacularly, three year revenue growth has ballooned by several orders of magnitude, thanks in part to the last 12 months of revenue growth. Therefore, it's fair to say the revenue growth recently has been superb for the company.
Shifting to the future, estimates from the analysts covering the company suggest revenue should grow by 24% per year over the next three years. With the industry only predicted to deliver 9.8% per annum, the company is positioned for a stronger revenue result.
With this in mind, it's not hard to understand why Inspire Medical Systems' P/S is high relative to its industry peers. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.
The Bottom Line On Inspire Medical Systems' P/S
The strong share price surge has lead to Inspire Medical Systems' P/S soaring as well. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
Our look into Inspire Medical Systems shows that its P/S ratio remains high on the merit of its strong future revenues. At this stage investors feel the potential for a deterioration in revenues is quite remote, justifying the elevated P/S ratio. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.
And what about other risks? Every company has them, and we've spotted 1 warning sign for Inspire Medical Systems you should know about.
If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Inspire Medical Systems, Inc.(紐約證券交易所代碼:INSP)的股東們會很高興看到股價經歷了一個不錯的月份,漲幅爲42%,並從先前的疲軟中恢復過來。不幸的是,上個月的漲幅幾乎沒有彌補去年的虧損,在此期間,該股仍下跌了20%。
繼公司價格反彈之後,與美國醫療設備行業的其他公司相比,Inspire Medical Systems的市銷率(或 “市盈率”)爲10.5倍,這可能使其看起來像是強勁的拋售。在美國,約有一半公司的市盈率低於3.4倍,甚至市盈率低於1.3倍也很常見。儘管如此,我們需要更深入地挖掘,以確定市盈率大幅上升是否有合理的基礎。
查看我們對 Inspire 醫療系統的最新分析
Inspire 醫療系統最近的表現如何?
Inspire Medical Systems的收入增長最近優於大多數其他公司,因此表現相對較好。市盈率可能很高,因爲投資者認爲這種強勁的收入表現將繼續下去。你真的希望如此,否則你會無緣無故地付出相當大的代價。
想全面了解分析師對公司的估計嗎?然後,我們關於Inspire Medical Systems的免費報告將幫助您發現即將發生的事情。
Inspire Medical Systems的收入增長趨勢如何?
只有當公司的增長有望在行業中脫穎而出時,你才能真正放心地看到像Inspire Medical Systems一樣高的市盈率。